Hormone replacement therapy

i-Health, Inc. Urges U.S. Congressional Leaders to Prioritize the Funding of Natural & Non-Hormonal Solutions for Menopause in Women's Health Research

Retrieved on: 
Monday, April 8, 2024
Health, Attention, Congress, Government, Veteran, White, SVP, Executive order, Research, Menopause, History, Woman, Data collection, Hormone replacement therapy, Breast cancer, HRT, Hot, Amerifit Brands

i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.

Key Points: 
  • i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.
  • Research gaps are especially prevalent for health conditions associated with women's midlife and later years, including perimenopause and menopause."
  • The latest Executive Order from President Biden aims to close research gaps on women's health across their lifespans.
  • i-Health, Inc. the company behind Estroven®, the leading brand in natural, non-hormonal menopause relief‡, is committed to driving meaningful change for often overlooked health issues.

Synthetic Hormones Market Research Report 2024: Development of New Delivery Systems and Formulations, & Demand for HRT - Global Analysis and Forecast, 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Pharmaceutical, Health, Other Health, Hospital, Peptide, Birth, Hypothyroidism, Biotechnology, Prevalence, Growth, Human body, Incidence, Insulin, Diabetes, Patient, Conditional sentence, Research, Menopause, World Health Organization, Investment, Skin, Hormone replacement therapy, Safety, HRT, WHO, Region, Administration, Ageing, Pharmaceutical industry

The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.

Key Points: 
  • The development of new delivery systems and formulations that enhance patient compliance and reduce side effects further fuels the market growth.
  • Overall, the synthetic hormones market is expected to continue growing, driven by the need for effective treatments for hormonal disorders and the ongoing research and development in this field.
  • The increasing occurrence of hormonal disorders, including hypothyroidism, diabetes, and imbalances, plays a crucial role in propelling the synthetic hormones market.
  • The hospital pharmacies segment accounted for the largest share of the global synthetic hormones market (by end user) in 2022.

Liquid Mobile Announces the Opening of Three New Locations in Texas

Retrieved on: 
Thursday, March 28, 2024
RN, Depression, Health, Sprint, Growth, Hormone replacement therapy, Partner (business rank), Partnership, Physician, Patient, Common, Anxiety, Influenza, Woman, Semaglutide, Kansas City metropolitan area, Safety, Privacy, Dallas Cowboys, FDA, Nursing, Weight loss, Migraine, Practitioner

KANSAS CITY, Mo. , March 28, 2024 /PRNewswire/ -- Liquid Mobile, a rapidly growing on-demand, mobile IV hydration and wellness service, announces the opening of three new locations in Texas, all situated within Cowboys Fit clubs - state-of-the-art fitness facilities in partnership with the Dallas Cowboys. With successful locations already established in the Kansas City and Phoenix metros, these new locations in Frisco, Plano, and Pflugerville mark an expansion of Liquid Mobile's commitment to advancing community health.

Key Points: 
  • Continuing its rapid growth, Liquid Mobile expands with new locations within Cowboys Fit clubs, extending on-demand and mobile wellness services to the Dallas and Austin metro areas.
  • , March 28, 2024 /PRNewswire/ -- Liquid Mobile, a rapidly growing on-demand, mobile IV hydration and wellness service, announces the opening of three new locations in Texas, all situated within Cowboys Fit clubs - state-of-the-art fitness facilities in partnership with the Dallas Cowboys.
  • Liquid Mobile, a rapidly growing on-demand, mobile IV hydration and wellness service, announces expansion into Texas.
  • Scheduled to launch in Texas on April 1, 2024, Liquid Mobile focuses on wellness and quick relief from ailments such as colds, flu, migraines, and more.

Empowering Wellness: PÜR LIFE Medical of Fishers Introduces Innovative Health Solutions

Retrieved on: 
Wednesday, March 27, 2024
Obesity, Exercise, Inflammation, Weight loss, Chronic pain, Quality of life, Arthritis, Hormone replacement therapy, Pain, Fatigue, Fisher

FISHERS, Ind., March 27, 2024 /PRNewswire/ -- PÜR LIFE Medical of Fishers is redefining the healthcare landscape with personalized healthcare services, tailored to individuals seeking holistic solutions to their health challenges.

Key Points: 
  • FISHERS, Ind., March 27, 2024 /PRNewswire/ -- PÜR LIFE Medical of Fishers is redefining the healthcare landscape with personalized healthcare services, tailored to individuals seeking holistic solutions to their health challenges.
  • PÜR LIFE's approach to hormone and gut health optimization involves a comprehensive evaluation of each patient's medical history, symptoms, and lifestyle factors.
  • At PÜR LIFE, the medical team specializes in comprehensive joint care, offering a range of treatment options to address pain, inflammation, and functional limitations.
  • For further details about PÜR LIFE Medical of Fishers and its services, please visit their website at purlifemedicalfishers.com .

Serotonin Anti-Aging Centers to Debut in Chicagoland with 3-Unit Development Deal

Retrieved on: 
Thursday, March 21, 2024
Health, Collagen induction therapy, Elective surgery, Economic development, Overalls, PRP, Hormone replacement therapy, Happiness, HRT, Day, Map, HBOT, Fast food

CHICAGO, March 21, 2024 /PRNewswire/ -- Serotonin Anti-Aging Centers announced today the upcoming opening of three new locations in the Chicago suburbs. The nation's fastest growing anti-aging/longevity franchise plans to open the doors to its first location in DuPage County within the year.

Key Points: 
  • CHICAGO, March 21, 2024 /PRNewswire/ -- Serotonin Anti-Aging Centers announced today the upcoming opening of three new locations in the Chicago suburbs.
  • When searching for new business opportunities, Aboobaker was drawn toward optimizing the health of Chicagoland residents with the science-backed services of Serotonin.
  • "Awarding this franchise to Pilakka is a fantastic opportunity for the Serotonin brand national footprint," said Eric Casaburi, Founder and CEO of Serotonin Anti-Aging Centers.
  • To learn more about Serotonin Anti-Aging Centers and its franchising opportunities, visit www.serotonincenters.com/franchising/ .

The Inner Circle Acknowledges, Ricardo Revilla, MD as a Pinnacle Life Professional

Retrieved on: 
Monday, February 26, 2024
Dorado, Woman, Hormone replacement therapy, Inner circle, Multimedia, Education, Medical specialty, AHEC, Emergency medicine, Anesthesia, Judgement, Patient, KEY, Wellness, Disease, Medicine, Nursing

KEY BISCAYNE, Fla., Feb. 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Ricardo Revilla, MD, is acknowledged as a Pinnacle Life Professional for his contributions to the Medical Field.

Key Points: 
  • KEY BISCAYNE, Fla., Feb. 26, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Ricardo Revilla, MD, is acknowledged as a Pinnacle Life Professional for his contributions to the Medical Field.
  • He completed residency in anesthesia at Ameijeiras Brothers Hospital in Havana; and a family medicine residency at the AHEC program in El Dorado, Arkansas.
  • Before moving to the United States, he practiced as an anesthesiologist in Cuba.
  • Board-certified as a family physician, Dr. Revilla is the owner and medical director at The Center for Wellness and Hormonal Balance.

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

Retrieved on: 
Friday, January 26, 2024
Senior, Hormone replacement therapy, Patient, Prostate cancer, ASCO, Prostate-specific antigen, CYP11A1, LBD, Mutation, Adrenal insufficiency, PSA, Safety, Research, Cancer, Growth, Pharmaceutical industry

Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations.

Key Points: 
  • Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations.
  • The new data reports initial results in an extension cohort of mainly AR-LBD wild-type patients combined with previously reported phase 2 data (AR-LBD mutation-positive only).
  • Data from the Phase II CYPIDES trial suggest that ODM-208/MK-5684 potently inhibits all steroid-hormone biosynthesis with observed antitumor activity in a heavily pretreated mCRPC population, especially in patients with AR-LBD mutations.
  • In Phase II CYPIDES, at data cut-off, a total of 134 previously treated mCRPC patients received 5mg of ODM-208/MK-5684 twice a day with glucocorticoid/mineralocorticoid replacement and ongoing androgen-deprivation therapy.

Serotonin Anti-Aging Centers to Debut in Texas with 6-Unit Development Deal

Retrieved on: 
Friday, January 26, 2024
Vitae, Hormone replacement therapy, Patient, PRP, MD, Health, Collagen induction therapy, Elective surgery, Athlete, HBOT, Map, HRT, DFW, Day, Growth

DALLAS, Jan. 26, 2024 /PRNewswire/ -- Optimus Vitae LLC announced today the upcoming opening of six new Serotonin Anti-Aging Centers in the Dallas-Fort Worth Metropolitan market. The nation's fastest growing anti-aging/longevity franchise plans to open the doors to its first two locations in Fort Worth and Mansfield within a year.

Key Points: 
  • DALLAS, Jan. 26, 2024 /PRNewswire/ -- Optimus Vitae LLC announced today the upcoming opening of six new Serotonin Anti-Aging Centers in the Dallas-Fort Worth Metropolitan market.
  • "The growth in Texas mirrors the growth of Serotonin and I'm excited to see the impact we will have on the health and performance of the great people of Texas."
  • With 97 franchises open and under development, Serotonin is positioned to lead the MedSpa and anti-aging industries just as demand in the sector escalates.
  • To learn more about Serotonin Anti-Aging Centers and its franchising opportunities, visit www.serotonincenters.com/franchising/ .

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Friday, January 5, 2024
MSD, Patient, CYP11A1, Orion, HRT, Hormone replacement therapy, Prostate cancer, Orion Corporation, Merck & Co., Research, Corporation, Merck, OS, Taxane, Development, Senior, Pharmaceutical industry

Orion Corporation (“Orion”) and MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) have initiated two pivotal Phase 3 clinical trials evaluating ODM-208/MK5684, an investigational CYP11A1 inhibitor, in combination with hormone replacement therapy (HRT), for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • Orion Corporation (“Orion”) and MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) have initiated two pivotal Phase 3 clinical trials evaluating ODM-208/MK5684, an investigational CYP11A1 inhibitor, in combination with hormone replacement therapy (HRT), for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).
  • Patients are now enrolling in the trials, named OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650).
  • The primary endpoints are overall survival (OS) and radiographic progression-free survival (rPFS) by AR LBD mutation status.
  • Secondary endpoints include time to first subsequent therapy (TFST), objective response rate (ORR) and duration of response (DOR).

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

Retrieved on: 
Wednesday, December 27, 2023
Prostate cancer, Adrenal insufficiency, Orion, LBD, Hormone replacement therapy, NEJM, Research, Testosterone, Mutation, Prostate-specific antigen, Patient, Safety, CYP11A1, Senior, Pharmaceutical industry

The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).

Key Points: 
  • The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).
  • Results from the Phase I/IIa CYPIDES trial suggest that ODM-208 potently inhibits all steroid-hormone biosynthesis with observed antitumor activity in a heavily pretreated mCRPC population, especially in patients with androgen receptor gene (AR) ligand-binding-domain (LBD) mutations.
  • In Phase I/IIa CYPIDES, a total of 92 previously treated mCRPC patients received 5mg of ODM-208 twice a day with glucocorticoid/mineralocorticoid replacement and ongoing androgen-deprivation therapy.
  • In phase I, 20 out of the total 47 patients had AR LBD mutation.